Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720494 | 0.85 | MAPT (0.72) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8878038 | 0.85 | MAPT (0.62) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5885563 | 0.84 | MAPT (0.70) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL900124 | 0.84 | MAPT (0.70) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5605709 | 0.83 | ALDH1A1 (0.66) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12297020 | 0.82 | ALDH1A1 (0.69) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5010663 | 0.82 | MAPT (0.68) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13130067 | 0.82 | MAPT (0.68) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6983298 | 0.82 | MAPT (0.68) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7977253 | 0.82 | MAPT (0.68) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107098871-B | Phenyl propionamide derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3006431-B1 | TIZOXANIDE CARBAMATE AND PHARMACEUTICAL USE THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2019-01-30 | — | — | EP | disclosed |
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20160340326-A1 | Tizoxanide Carbamate and Pharmaceutical Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2016-11-24 | — | — | US | disclosed |
| US-20160340326-A1 | Tizoxanide Carbamate and Pharmaceutical Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2016-11-24 | — | — | US | disclosed |
| EP-3092229-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2016-11-03 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| WO-2015103509-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015089327-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340326-A1 | Tizoxanide Carbamate and Pharmaceutical Use Thereof | CYP2C9, CA9, CYP3A7 | MAPT 1657/4885ALDH1A1 1653/4885CYP3A4 18/4885 |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, LYN | MAPT 4569/4885ALDH1A1 4256/4885CYP3A4 2782/4885 |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | ABL1, BTK, LYN | MAPT 4569/4885ALDH1A1 4256/4885CYP3A4 2782/4885 |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | MAPT 385/4885ALDH1A1 1327/4885CYP3A4 387/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | MAPT 314/4885ALDH1A1 1269/4885CYP3A4 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.